SB216763

For research use only. Not for use in humans.

目录号:S1075

SB216763 Chemical Structure

CAS No. 280744-09-4

SB216763 是一种有效的,选择性GSK-3α抑制剂,IC50为34.3 nM;对GSK-3β具有同样的抑制作用。SB216763 可激活自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1351.27 现货
RMB 1218.72 现货
RMB 2208.01 现货
RMB 7122.58 现货
RMB 8763.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SB216763发表文献73篇:

产品安全说明书

GSK-3抑制剂选择性比较

生物活性

产品描述 SB216763 是一种有效的,选择性GSK-3α抑制剂,IC50为34.3 nM;对GSK-3β具有同样的抑制作用。SB216763 可激活自噬。
靶点
GSK-3α [1]
(Cell-free assay)
GSK-3β [1]
(Cell-free assay)
34.3 nM ~34.3 nM
体外研究

除了抑制GSK-3α,SB 216763也同样有效作用于 GSK-3β,按10 μM 处理,抑制达96%, 作用于24 种其他蛋白激酶包括 PKBα 和PDK1时具有最小活性,IC50>10 μM。SB-216763作用于人肝脏细胞,刺激糖原合成,EC50为3.6 μM, 且作用于HEK293 细胞,诱导β-catenin-LEF/TCF相关报告基因的转录,这种作用存在剂量依赖性,按 5 μM处理,诱导达到最大值,增大2.5倍。[1]与剂量依赖性显著抑制GSK-3 活性一致,SB 216763 保护小脑颗粒神经元免受 LY-294002或钾丧失而诱导的细胞凋亡,这种作用具有浓度依赖性,3 μM 时保护神经达到最高值,与10 mM LiCl作用效果形成对比。3 μM SB 216763完全抑制 LY-294002诱导的 鸡背根神经节感觉神经元死亡。5 μM SB 216763 作用于HEK293细胞,显著抑制小脑颗粒神经元中GSK-3依赖的神经元特异性微管相关蛋白的磷酸化,且提高β-catenin细胞质水平,与Wnt调节的 GSK-3抑制效果差不多。[2] 25-50 μM SB 216763作用于前列腺癌细胞系,包括BXPC-3, MIA-PaCa2, PANC1, ASPC1, 和CFPAC, 降低细胞活力,这种作用存在剂量依赖性,且显著促进凋亡,处理72小时,凋亡达50%,而对HMEC或WI38细胞系没有作用效果。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NXT6fGs3TnWwY4Tpc44h[XO|YYm= NHjnXXVIdHmlb3flckB{gW62aHHz[UBi[3Srdnn0fUBw\iCKRVuyPVMh[2WubIOsJIlvcGmkaYTpc44hd2ZiR2PLN{1j\XSjLDDFR|UxRTBwMt88US=> M2\GfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN|MyLz5zMkm0NVM{OTxxYU6=
HEK293 MWTGeY5kfGmxbjDhd5NigQ>? MVTF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCxZjDjc41xd3WwZDDh[4FqdnO2IHfsfYNw\2WwIIP5cpRp[XOnIHvpcoF{\S1|IHnuJGhGUzJ7MzDj[YxteyxiRVO1NF0xNjMQvF2= NVPCeHliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxOFk3QDRpPkG1NVQ6Pjh2PD;hQi=>
MIAPaCa2 NGWxPXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnXzO|IhcHK| MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNTWFR[UOjMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwQVI2|ryP MlvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl|M{izOVUoRjF7M{O4N|U2RC:jPh?=
ST14A MnjzSpVv[3Srb36gZZN{[Xl? NFHVWWM3KGi{cx?= NIrk[IZKdmirYnn0bY9vKG:oIFfTT{0{NWKndHGtcYVlcWG2ZXSgW451KHOrZ37hcIlv\yCrbjDoeY1idiCVVEG0RUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gc4Yh[mW2YT3jZZNmcW5iYYLveY5lKG63Y3zleZMh[W[2ZYKgOkBpenNiYomgcYlkem:|Y3;wbYMh[W6jbInzbZM> NX;MRmpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3NFg6OzdpPkKwO|A5QTN5PD;hQi=>
neural precursor cells MV;GeY5kfGmxbjDhd5NigQ>? NG\3SIJKdmirYnn0bY9vKG:oIH7leZJwe3CqZYLlJJBzd2yrZnXyZZRqd25ib3[gcY92e2VibnX1doFtKHC{ZXP1dpNweiClZXzsd{BjgSCPVGSgZZN{[Xl? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N|E9N2F-
ReNcell VM NGC2SmtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MknwN{B2VQ>? Mm\TO|IhcHK| MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKnTnPlcIwhXk1iY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBifCB|IIXNJIFnfGW{IEeyJIhzew>? MojwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB5MEi5N|coRjJyN{C4PVM4RC:jPh?=
HepG2 MULGeY5kfGmxbjDhd5NigQ>? NFHTSY4{PCC3TR?= NGizSosyOiCqcoO= NVXMblN{UW6lcnXhd4UhcW5iZ3z1Z49{\SCrbnPvdpBwemG2aX;uJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG2IEO0JJVOKGGodHXyJFEzKGi{czDifUBodHWlb4PlJIF{e2G7 MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkexOVAoRjJ3NE[3NVUxRC:jPh?=
3T3L1 MWTGeY5kfGmxbjDhd5NigQ>? NEHjNZY{PCC3TR?= NVz0SY1POTJiaILz M2XvT2lv[3KnYYPlJIlvKGeudXPvd4UhcW6lb4Lwc5JifGmxbjDpckBud3W|ZTCzWFNNOSClZXzsd{BifCB|NDD1UUBi\nSncjCxNkBpenNiYomg[4x2[2:|ZTDhd5NigQ>? NVz4e4N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlcyPTBpPkK1OFY4OTVyPD;hQi=>
HepG2 M1:4eGZ2dmO2aX;uJIF{e2G7 MXSzOEB2VQ>? MXuxNkBpenN? MU\Jcohq[mm2aX;uJI9nKEeVS{Pi[ZRiKGmwIHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHKjdHnvJI9nKHCqb4PwbI9zgWyjdHXkJGdUN0eVIHH0JFM1KHWPIHHmeIVzKDF{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NETIeJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2O|E2OCd-MkW0OlcyPTB:L3G+
Sf9 NIHLZ2NHfW6ldHnvckBie3OjeR?= MlPCN|AhdWmw MXrJcohq[mm2aX;uJI9nKEeVS{Pi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCJU{GgZZMhe3Wkc4TyZZRmKGGwZDDb[4FudWF|Mm3BWHAh[W[2ZYKgN|AhdWmwIHL5JJNkcW6rdHzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yM{O4PO69VQ>? NHzZUFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human HDLM-2 cell NHHJXXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUXTXXRDUW6qaXLpeIlwdiCxZjDoeY1idiCKRFzNMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyOUi0JO69VQ>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H1770 cell NUDHVYp5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDZcVB4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1yLkK5N|kzKM7:TR?= NGTtfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human HOP-62 cell NXvwdW1MT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnnTTY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg2OjV4IN88US=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human JAR cell NEO4cFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMkGwOFQh|ryP NYPMZYN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human K5 cell NIrNOGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVjiSVlnUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6NCCLQ{WwQVEvPTN4OUig{txO NV;XTINYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human MV-4-11 cell NGi4ZZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{npU2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjl4OEWg{txO NXfGRZZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BT-549 cell M{PrT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mm\hTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6Ozd4IN88US=> NEnIfIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human LB2241-RCC cell NFzyW|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjJ2MT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR{OEe0JO69VQ>? M{fSZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human GAMG cell M{W4cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEnVe5FKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PDB7IN88US=> NGW0emc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human HMV-II cell NV:yOllPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnvCTY5pcWKrdHnvckBw\iCqdX3hckBJVVZvSVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlY4PjB5IN88US=> NGmxe|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human RS4-11 cell M4W2O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHUTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI1OTRzIN88US=> MlPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H1993 cell M1Wz[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHTDS3lKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVk6OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRThwM{[1N|Qh|ryP NWLZdZNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human IST-SL1 cell M4XJSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWPJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlAzODRizszN NH7PeIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human SK-OV-3 cell Mo\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mly3TY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4yODB{IN88US=> M2PqNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human ESS-1 cell M1fLT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnTjTY5pcWKrdHnvckBw\iCqdX3hckBGW1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuOVk5PzJizszN M3nwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human G-361 cell M{LMbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCuNVc6QCEQvF2= M{ToflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human ALL-PO cell MlfTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHrRVoRKdmirYnn0bY9vKG:oIHj1cYFvKEGOTD3QU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjN2N{eg{txO MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NB5 cell M1\VNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJG5DPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkKxOVch|ryP MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human DU-145 cell NFnafGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvvfIxlUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS54NUO1JO69VQ>? MnzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NMC-G1 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2XOVGlvcGmkaYTpc44hd2ZiaIXtZY4hVk2FLVexJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPzJ4NDFOwG0> M1LqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human RPMI-7951 cell M{CyXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvN{m1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVEyNjd6NkSg{txO MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H2009 cell NFziVZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{NjJ2Mkeg{txO NW\KXGV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human LoVo cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\GR3ZKdmirYnn0bY9vKG:oIHj1cYFvKEyxVn:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{4{PzdzIN88US=> NWfLVJpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human A2058 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEzODV6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuOFY6KM7:TR?= NIPFeI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human D-566MG cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnHSTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTR6MTFOwG0> NGTMT2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human QIMR-WIL cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJHFKVVJvV1nMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvPjN7NDFOwG0> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human S-117 cell Mle5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUTzW2ZJUW6qaXLpeIlwdiCxZjDoeY1idiCVLUGxO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3NjRyMkKg{txO M1XQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human YH-13 cell NXy1WXJWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTGeoxsUW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3NjZ6NkWg{txO M{nJVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human IGROV-1 cell MnLUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{4zODBzIN88US=> NVXScmFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BHT-101 cell NIPTfodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXXcXNKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPy54MEm5JO69VQ>? NGC2PI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human MKN45 cell NHXud5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHzlTWZKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVgvPDF{ODFOwG0> NF;rU2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human A498 cell M17Semdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3[5fmlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlQ2PDlizszN Ml;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human U-266 cell M{DHWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuPFc6PyEQvF2= NVTwO442RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BFTC-905 cell M3npOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYToTFB4UW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJzLkG4O|kh|ryP NH\FZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human BxPC-3 cell MmriS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnvHTY5pcWKrdHnvckBw\iCqdX3hckBDgFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4{PTV2IN88US=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-SNU-1 cell M{O0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIW0eFFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJzLkW1OVgh|ryP MlfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SF539 cell M4HKT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4nzTGlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z3M{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNk4xOTl6IN88US=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human VA-ES-BJ cell M1z5eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkG2TY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIzNjV5NkOg{txO NHfN[XE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human HuO-3N1 cell NUfub4cyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH7CRVhKdmirYnn0bY9vKG:oIHj1cYFvKEi3Tz2zUlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOi54MUWxJO69VQ>? NHK3bJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human EM-2 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmjBTY5pcWKrdHnvckBw\iCqdX3hckBGVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkKuOlY5QSEQvF2= NFnwNnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human T98G cell M2DCXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Mz6zNFA6KM7:TR?= NIDnbo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human SW1783 cell NVO4WWlYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH75VnhKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUe4N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjV{NEOg{txO NFzCPJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NKM-1 cell M13iOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HneWlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yN{45PTF{IN88US=> MoTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human KOSC-2 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHzSXWJKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1NjF{OUKg{txO NVHyNHExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SW48 cell M2P0dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUDFUWgzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{S4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPjB4NzFOwG0> MoqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H28 cell NWTjc4RKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MU\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOU4zOTB2IN88US=> MlzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human 5637 cell NFXMNZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmXPTY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkWuPFEyOSEQvF2= MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NB69 cell NY\4NplbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXnJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nj6xO|Y1KM7:TR?= NWj0bmVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human HT-29 cell NUDwPIVqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuNVc2OiEQvF2= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human PFSK-1 cell NH3FeoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXnsZXpWUW6qaXLpeIlwdiCxZjDoeY1idiCSRmPLMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPy53OUOg{txO NIjOOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human UACC-257 cell M{nocWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;QSGc4UW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ5Lke0N{DPxE1? NXi0cYc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human D-423MG cell Ml;nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7rbXBKdmirYnn0bY9vKG:oIHj1cYFvKERvNEKzUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPy57MUC2JO69VQ>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NH-12 cell NELxR3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlPyTY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlQxPTlizszN MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human DEL cell NWjmRlBsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIXT[JdKdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK5MlA1PzRizszN M2G2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human LS-513 cell NXP2[4JMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NW\5V49SUW6qaXLpeIlwdiCxZjDoeY1idiCOUz21NVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{OC5zM{O0JO69VQ>? NH3qcY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human NBsusSR cell M{P0eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnnITY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|AvPTZ5ODFOwG0> MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human BV-173 cell M{e0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnW1TY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNE44PjR7IN88US=> NX\iNoF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human A101D cell MorUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDGN29iUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjl5OESg{txO M1jkVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human LU-134-A cell M2PuZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF|ND3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|EvODJ|ODFOwG0> MnXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human ES3 cell M3LVOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWfYcGhbUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{Ozd4IN88US=> NXfvZZZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human NY cell M4\zO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jOcWlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mj6yPVY2KM7:TR?= MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H1975 cell M33JfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHhTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG5O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Oi5|NUiyJO69VQ>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human A704 cell MmnaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfzSolKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4zODV7IN88US=> NWK1XW9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SK-MEL-24 cell NFnkT5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;QPGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwMkWyN{DPxE1? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human SW1088 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NETNcppKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjN2NUKg{txO NGi0ZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK|5USU6JRWK8M4E,
human SK-MEL-1 cell Mn\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDwUnlKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImsJGlEPTB;M{SuO|E1KM7:TR?= M3fjZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human MOLT-4 cell M1PLZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUXJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO2MlE1PjdizszN M{DndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human T47D cell NXzFOYo5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{X1NmlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlE3PDdizszN NX\JfXpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SW1710 cell NXizOItYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWWxe2FkUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Py5|NkC4JO69VQ>? MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human MKN7 cell MmO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXUZpFKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE4xQTB7IN88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human CAL-72 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkXETY5pcWKrdHnvckBw\iCqdX3hckBESUxvN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE4yOTd6IN88US=> M4izSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human AGS cell M{HI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHryRXhKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO4MlIxOzlizszN NUXxbGxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BE-13 cell NEfOPFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NELLZplKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|gvPzd6MzFOwG0> Mnz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human Calu-6 cell M{PTXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYfJcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO5MlY6PjRizszN M2j4blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human CAL-27 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS0MlAxPTRizszN MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human BB49-HNC cell MlG2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGJDPDlvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFQvODJ5ODFOwG0> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
c-Myb; 

PubMed: 21795403     


Jurkat, K562, and RPMI 8226 cells were treated with or without 5 or 10 μM SB216763 for 8 h, and cell lysates were analyzed by immunoblotting. 

pGSK-3β / GSK-3β / E2F1 / β-catenin ; 

PubMed: 28042322     


Inhibition of GSK3β increased LSH expression. U251 (A) and HS683 (B) with treatment of SB216763 with different concentration as indicated were examined for the expression of LSH, p-GSK3β, GSK3β, E2F1, β-catenin and GAPDH by Western analysis. U251 (C) and HS683 (D) with treatment of 10μM SB216763 with time as indicated were examined for the expression of LSH, p-GSK3β, GSK3β, E2F1, β-catenin and GAPDH by Western analysis.

21795403 28042322
Growth inhibition assay
Cell viability; 

PubMed: 24779365     


Cell viability of mouse embryonic stem cells after exposure to GSK3 inhibitors. (A) Cell viability of the mouse embryonic stem cell line ES-D3 after a three day treatment with different concentrations of BIO, SB-216763, CHIR-99021 and CHIR-98014. Cell viability was measured with the MTT assay. DMSO without inhibitors was used as vehicle control. Data are expressed as percentages normalized to the control condition without inhibitors. (B) Cell viability of the mouse embryonic stem cell line ES-CCE after a three day treatment with different concentrations of BIO, SB-216763, CHIR-99021 and CHIR-98014. Values are means ± SEM, n = 3-5. ANOVA plus Dunnett’s post hoc test. ** p ≤ 0.01, * p ≤ 0.05 compared to the control.

24779365
体内研究 SB 216763 按20 mg/kg 剂量处理患Bleomycin (BLM)诱导肺部炎症和纤维化的小鼠,通过显著抑制炎症细胞因子MCP-1和TNF-α的产量,显著抑制肺部炎症和纤维化,且显著提高BLM处理小鼠的寿命。SB 216763 处理,通过抑制肺泡上皮细胞损伤,而显著降低 BLM诱导的肺泡。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

GSK-3 活性检测:

在不同浓度SB 216763存在时,在含1 nM 人GSK-3α, 50 mM MOPS pH 7.0,0.2 mM EDTA, 10 mM Mg(Ac)2,7.5 mM β-巯基乙醇,5% (w/v)甘油,0.01% (w/v) Tween-20, 10% (v/v) DMSO, 及28 μM GS-2 肽底物的反应混合物中,测量GSK-3激酶活性。GS-2肽序列对应GSK-3使糖原合酶磷酸的地区。加入0.34 μCi [33P]γ-ATP开始实验。全部ATP浓度为 10 μM。实验在室温下进行30分钟后,加入含21 mM ATP的1/3实验体积为2.5%(v/v) H3PO4,终止反应。样本在P30磷酸纤维垫上展开,然后在0.5% (v/v) H3PO4中冲洗6次。过滤垫密封到Wallac betaplate闪烁液的样品袋中。在 Wallac microbeta闪烁计数器中计算测定33P 渗透到底物肽中的量。
细胞实验:[3]
- 合并
  • Cell lines: BXPC-3, MIA-PaCa2, PANC1, ASPC1, 和CFPAC
  • Concentrations: 溶于DMSO, 终浓度为~50 μM
  • Incubation Time: 24, 48, 和72小时
  • Method: 使用不同浓度SB 216763处理细胞 24,48和 72小时。通过MTS检测测量相对细胞活力。使用 Hoechst染色而测定凋亡细胞。
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 患Bleomycin (BLM)诱导的肺部炎症和纤维化的C57BL/6N小鼠
  • Dosages: 20 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (61.95 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+corn oil
4mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 371.22
化学式

C19H12N2O2Cl2

CAS号 280744-09-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

相关GSK-3产品

Tags: 购买SB216763 | SB216763供应商 | 采购SB216763 | SB216763价格 | SB216763生产 | 订购SB216763 | SB216763代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID